Anchor>
DSK subsidiary Protox has completed its Botox production plant. Bio plants and even botox are now not uncommon materials. However, it is meaningful because it is the result of the company overcoming adversity. Reporter Dae-ho Lee covered the story.

Reporter>
Protox bio production plant located in Hyangnam Pharmaceutical Complex, Hwaseong-si, Gyeonggi-do.

Two years after construction began, the tape announcing the completion was cut.

Total floor area of ​​6,227m² (approximately 1,886 pyeong), 4 floors above ground. We have a GMP facility capable of producing approximately 2.7 million vials of Botox (Protoxin) per year.

Although Protox is a latecomer to Botox (Protoxin), we are confident that it will have sufficient differentiation.

[Lee Dong-beom / Protox CEO: The effect usually lasts for about 6 months, but ours is our own record, but we are somewhat confident that it will last for more than a year. That’s the beauty of the product. Wouldn’t that be preferred by patients because the pain is a bit milder? .]

This completion ceremony has a special meaning.

This is because the parent company, DSK, almost lost its management rights to corporate hunters in 2017, and even suffered from delisting due to their embezzlement.

In the end, founder Vice Chairman Kim Tae-gu won the legal battle, and Synergy Partners emerged as an ally and was able to settle the dispute.

[Kim Jong-won / CEO of DSK Bio Division: As we entered the conflict, we had to do our best, and it matched our concept, so we started managing and it seemed like a natural progression.] In the past, we met the wrong corporate hunter and were on the verge of bankruptcy

. DSK and its subsidiary Protox.

After two years of hardship, we are now on track for new growth.

[Money Today Broadcasting MTN = Reporter Lee Dae-ho ( robin@mtn.co.kr )]